Question 1

Question 2

Do any of the new BioBrick parts (or devices) that you made this year raise any safety issues? If yes, did you document these issues in the Registry? how did you manage to handle the safety issue? How could other teams learn from your experience?

The most common question people would have judged us is how we make sure that it is safe to deliver this bug into human intestine. As we noted, the output we would like to deliver, GLP-1, is innate naturally and haven’t proven any significant harms to the human body. Cell penetrating peptides, which is another peptide we are going to deliver into gastroenterological tract, do no harm as well, since it has a pretty short half life (<15 mins) inside GI tract. What’s more, intestine is an organ with an abundance of normal flora, mainly consisting of Streptococcus and Lactobacillus in the middle intestine. In ileum and section close to ileo-cecal valve, bacteroides and coliform bacteria are dominant. First, for the E. coli itself, it’s very hard to colonize in the GI tract as it would face a bunch of competitors over nutrients and space. Second, the bugs we are going to deliver inside human body is pretty fragile, which can be easily eliminated by some antibiotics, 2nd generation cephalosporin, high ampicillin plus sulbactam, or erythromycin, which is ideal of usage in our cases, since it not only provided anti-microbial effects, but also increases the motility of intestine. Above all, the design we are going to bring to synthetic biology community has little safety concerns, and can be easily circumvented or adjusted.

Question 3

Question 4